logo

FDA Calendar

Share
Company Name Amgen Inc.
Drug Name BLINCYTO (sBLA)
Event Name FDA decision on BLINCYTO for the treatment of MRD in patients with acute lymphoblastic leukemia
Event Date 03/29/2018
Outcome Date 03/29/2018
Outcome FDA approves BLINCYTO for the treatment of MRD in patients with acute lymphoblastic leukemia
Drug Status
Rival Drugs
Market Potential
Other Approvals BLINCYTO is already approved for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
News
Return to FDA Calendar